Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma

Keyphrases

• Clinical Outcomes 100%
• Lymphoma 100%
• Chimeric Antigen Receptor T Cells (CAR-T) 100%
• Toxicity Outcomes 100%
• Early Toxicity 100%
• Cytokine Release Syndrome 100%
• Neurotoxicity 40%
• Overall Survival 30%
• Disease Outcome 30%
• Cardiotoxicity 30%
• Progression-free Survival 30%
• Cell Infusion 20%
• Disease Response 20%
• Toxicity Grades 20%
• Multivariable Regression 20%
• Fever 10%
• Corticosteroids 10%
• Large Cohort 10%
• Blood Pressure 10%
• Relapsed Lymphoma 10%
• Adult Patients 10%
• Hypotension 10%
• High Prevalence 10%
• As(III) 10%
• Disease Severity 10%
• Clinical Measures 10%
• Median Time 10%
• Long-term Disease 10%
• Direct Therapy 10%
• Complete Response 10%
• Single-agent Therapy 10%
• Cardiac Events 10%
• Lymphoma Patients 10%
• Laboratory Measures 10%
• Refractory Lymphoma 10%
• Anti-cytokine 10%
• Long Progression-free Survival 10%
• Tocilizumab 10%
• Relapsed/refractory 10%
• Significant Trends 10%
• Early Cytokines 10%

Nursing and Health Professions

• Clinical Outcome 100%
• Chimeric Antigen Receptor T-Cell Immunotherapy 100%
• Cytokine Release Syndrome 100%
• Diseases 50%
• Economic and Social Development 50%
• Progression Free Survival 40%
• Neurotoxicity 40%
• Overall Survival 30%
• Cardiotoxicity 30%
• Chimeric Antigen Receptor T-Cell 30%
• Infusion 20%
• Prevalence 10%
• Blood Pressure 10%
• Hypotension 10%
• Disease Severity 10%
• Cardiac Event 10%
• Corticosteroid 10%
• Tocilizumab 10%

Medicine and Dentistry

• Chimeric Antigen Receptor T-Cell Immunotherapy 100%
• Cytokine Release Syndrome 100%
• Diseases 50%
• Progression Free Survival 40%
• Neurotoxicity 40%
• Overall Survival 30%
• Cardiotoxicity 30%
• Chimeric Antigen Receptor T-Cell 30%
• Infusion 20%
• Prevalence 10%
• Blood Pressure 10%
• Hypotension 10%
• Disease Severity 10%
• Tocilizumab 10%
• Corticosteroid 10%
• Long-Term Outcome 10%